{"id":30743,"date":"2018-10-26T18:04:10","date_gmt":"2018-10-26T12:34:10","guid":{"rendered":"https:\/\/blog.forumias.com\/?p=30743"},"modified":"2018-10-26T18:04:10","modified_gmt":"2018-10-26T12:34:10","slug":"who-launches-plan-for-cheaper-tb-drugs","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/who-launches-plan-for-cheaper-tb-drugs\/","title":{"rendered":"WHO launches plan for cheaper TB drugs"},"content":{"rendered":"<p><a href=\"http:\/\/www.thehindu.com\/todays-paper\/tp-national\/who-launches-plan-for-cheaper-tb-drugs\/article22988596.ece\"><b>WHO launches plan for cheaper TB drugs<\/b><\/a><\/p>\n<p><b>Context:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The World Health Organization (WHO) recently invited pharmaceutical companies around the world to submit proposals to manufacture affordable version of newer medicines for treatment of drug resistant tuberculosis.<\/span><\/li>\n<\/ul>\n<p><b>Introduction:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">India has nearly 1.3 lakh DR-TB patients. However, the Health Ministry gets only 10,000 doses of Bedaquiline and 400 doses of Delaminid.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The medicines are obtained as donations from Janssen(US) and Otsuka Pharmaceuticals(Japan), the respective manufacture.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">In the case of HIV, one company, Cipla, came up with a \u2018AIDS cocktail\u2019 combination of Stavudine, Lamivudine and Nevirapine, enabling effective treatment.<\/span><\/li>\n<\/ul>\n<p><b>Purpose:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The aim was to replicate the success of <\/span><b>addressing the HIV epidemic.<\/b><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">One of the aims is to a<\/span><b>chieve more competitive market and more affordable prices.<\/b><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Inclusion within the scope of PQ has also incentivised the development of fixed dose combinations, which have yielded much better results for patients.<\/span><\/li>\n<\/ul>\n<p><b>Expression of Interest (EoI):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">WHO has requested drug makers to submit an <\/span><b>Expression of Interest (EoI)<\/b><span style=\"font-weight: 400;\"> for Bedaquiline and Delaminid, two new-generation drugs, recommended for drug resistant-TB.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\"> Under WHO norms, drugs submitted upon such requests and complying with its standards are included in a list for procurement by the UN and other organisations.<\/span><\/li>\n<\/ul>\n<p><b>Trade Related Intellectual Property Rights (TRIPS):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Cheaper drugs to treat HIV became possible at the time as the<\/span><b> Indian Patents Act <\/b><span style=\"font-weight: 400;\">did not provide for product patents on pharmaceutical products, until required by the <\/span><b>Trade Related Intellectual Property Rights (TRIPS)<\/b><span style=\"font-weight: 400;\"> framework of the World Trade Organization (WTO).<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">India became TRIPS compliant with pharma product patents in 2005.<\/span><\/li>\n<\/ul>\n<p><b>Access to affordable drugs:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">With WHO\u2019s backing, India will be able to accelerate introduction of generics.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Inclusion of the two new drugs, <\/span><b>Bedaquiline and Delaminid, <\/b><span style=\"font-weight: 400;\">in the pre-qualification call is being interpreted by aid agency <\/span><b>M\u00e9decins Sans Fronti\u00e8res (MSF)<\/b><span style=\"font-weight: 400;\"> as WHO\u2019s backing for generics.<\/span><\/li>\n<\/ul>\n<p><b>To address challenges of drug-resistant:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">WHO considers the two drugs key compounds to address challenges of drug-resistant TB.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">WHO also want to encourage generic competition to start finding ways to make these medicines available in countries where they are not yet registered.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The EoI allows generics manufacturers interested in producing these two drugs, and currently facing technical challenges, to address their questions to WHO\u2019s pre-qualification team.<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>WHO launches plan for cheaper TB drugs Context: The World Health Organization (WHO) recently invited pharmaceutical companies around the world to submit proposals to manufacture affordable version of newer medicines for treatment of drug resistant tuberculosis. Introduction: India has nearly 1.3 lakh DR-TB patients. However, the Health Ministry gets only 10,000 doses of Bedaquiline and&hellip; <a class=\"more-link\" href=\"https:\/\/forumias.com\/blog\/who-launches-plan-for-cheaper-tb-drugs\/\">Continue reading <span class=\"screen-reader-text\">WHO launches plan for cheaper TB drugs<\/span><\/a><\/p>\n","protected":false},"author":61,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[555],"tags":[],"class_list":["post-30743","post","type-post","status-publish","format-standard","hentry","category-test-1","entry"],"jetpack_featured_media_url":"","views":{"total":0,"cached_at":"","cached_date":1704741231},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/30743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=30743"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/30743\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=30743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=30743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=30743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}